

Olga T Filippova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6620545/publications.pdf>

Version: 2024-02-01

19
papers

294
citations

1040056

9
h-index

940533

16
g-index

19
all docs

19
docs citations

19
times ranked

387
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Evaluation of a New Frailty Index for Older Surgical Patients With Cancer. <i>JAMA Network Open</i> , 2019, 2, e193545.	5.9	77
2	It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 555-561.	1.4	29
3	Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center. <i>Gynecologic Oncology</i> , 2019, 154, 77-82.	1.4	24
4	A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. <i>Gynecologic Oncology</i> , 2020, 158, 608-613.	1.4	23
5	Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e17.	2.2	22
6	A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 433-437.	1.4	16
7	Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. <i>Gynecologic Oncology</i> , 2020, 159, 434-441.	1.4	16
8	Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 687-692.	1.4	14
9	Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. <i>Gynecologic Oncology</i> , 2020, 159, 66-71.	1.4	12
10	Cancer Prevention and Screening for Older Adults: Part 1. Lung, Colorectal, Bladder, and Kidney Cancer. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2399-2406.	2.6	9
11	Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort. <i>Gynecologic Oncology</i> , 2021, 163, 294-298.	1.4	9
12	Cancer Prevention and Screening for Older Adults: Part 2. Interventions to Prevent and Screen for Breast, Prostate, Cervical, Ovarian, and Endometrial Cancer. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2684-2691.	2.6	8
13	Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women. <i>Gynecologic Oncology</i> , 2021, 161, 545-552.	1.4	8
14	Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1377-1380.	2.5	7
15	Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1554-1561.	2.5	7
16	Pattern of disease and response to pembrolizumab in recurrent cervical cancer. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100831.	0.6	4
17	Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1183-1188.	2.5	4
18	The current clinical approach to newly diagnosed uterine cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 581-590.	2.4	3

#	ARTICLE	IF	CITATIONS
19	Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>Gynecologic Oncology</i> , 2021, 160, 51-55.	1.4	2